Keratinocyte growth factor.

Mucositis occurs in over 90% of patients undergoing stem cell transplantation for hematological malignancies. It is associated with significant morbidity in the form of pain, dysphagia and decreased oral intake, as well as mortality. Palifermin is a recombinant keratinocyte growth factor that has been shown to be effective in decreasing the incidence, severity and duration of mucositis in Phase III trials. Improvement in patient functioning during hematopoietic stem cell transplants has also been reported. This review deals with the preclinical data and the clinical trials that have been carried out with this agent in patients with hematologic malignancies. In addition limited Phase I and II data on solid tumors is available and will be included.
AuthorsUzma Athar, Teresa C Gentile
JournalExpert opinion on biological therapy (Expert Opin Biol Ther) Vol. 9 Issue 6 Pg. 779-87 (Jun 2009) ISSN: 1744-7682 [Electronic] England
PMID19456212 (Publication Type: Journal Article, Review)
Chemical References
  • Fibroblast Growth Factor 7
  • Fibroblast Growth Factor 7 (therapeutic use)
  • Hematopoietic Stem Cell Transplantation (adverse effects)
  • Humans
  • Mucositis (drug therapy, etiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: